Kirk R. Henne, Ph.D.

Affiliations: 
2001 University of Washington, Seattle, Seattle, WA 
Area:
Pharmaceutical Chemistry
Google:
"Kirk Henne"
Mean distance: (not calculated yet)
 

Parents

Sign in to add mentor
Allan E. Rettie grad student 2001 University of Washington
 (The active site characteristics of the cytochrome P450 4B1 bioactivation enzyme.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Baer BR, Rettie AE, Henne KR. (2005) Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate. Chemical Research in Toxicology. 18: 855-64
Zheng YM, Baer BR, Kneller MB, et al. (2003) Covalent heme binding to CYP4B1 via Glu310 and a carbocation porphyrin intermediate. Biochemistry. 42: 4601-6
Zheng YM, Henne KR, Charmley P, et al. (2003) Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicology and Applied Pharmacology. 186: 119-26
Zheng Y, Baer B, Kneller M, et al. (2003) 559 Mechanistic studies of covalent heme binding to CYP4B1 Toxicology Letters. 144: s150
Henne KR, Kunze KL, Zheng YM, et al. (2001) Covalent linkage of prosthetic heme to CYP4 family P450 enzymes. Biochemistry. 40: 12925-31
Henne KR, Fisher MB, Iyer KR, et al. (2001) Active site characteristics of CYP4B1 probed with aromatic ligands. Biochemistry. 40: 8597-605
Haining RL, Jones JP, Henne KR, et al. (1999) Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry. 38: 3285-92
Henne KR, Gaedigk A, Gupta G, et al. (1998) Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. Journal of Chromatography. B, Biomedical Sciences and Applications. 710: 143-8
Steward DJ, Haining RL, Henne KR, et al. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 7: 361-7
Haining RL, Steward DJ, Henne KR, et al. (1997) Correlation of the cytochrome P450 2C9 LeuA9 defect with warfarin sensitivity Faseb Journal. 11
See more...